## MTD: Mettler-Toledo International, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.0% below STRENGTH zone (4.0-10.0%); PEG 5.76 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1334.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Assenagon Asset Management S.A. Purchases 2,408 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251219T090843 | Somewhat-Bullish | Relevance: 100%
- Assenagon Asset Management S.A. increased its stake in Mettler-Toledo International, Inc. by 13.7% in the third quarter, purchasing an additional 2,408 shares to now own 19,935 shares valued at approximately $24.47 million. The company's Q3 earnings beat estimates, with a reported EPS of $11.15 against a consensus of $10.62 and revenues of $1.03 billion. Analyst ratings are mixed, with several recent upgrades to "Buy" and new "Neutral" or "Equal Weight" initiations, leading to an average target price of $1,441.67.

**2. Thrivent Financial for Lutherans Sells 9,989 Shares of Mettler-Toledo International, Inc. $MTD**
- Source: MarketBeat | 20251218T105936 | Neutral | Relevance: 97%
- Thrivent Financial for Lutherans has significantly reduced its stake in Mettler-Toledo International by selling 9,989 shares, decreasing its holdings by 53.6%. Insiders have also been net sellers, disposing of over 19,000 shares worth approximately $28.68 million in the past three months. Despite these sales, Mettler-Toledo International recently surpassed Q3 earnings estimates and received a mixed "Hold" rating from analysts with an average target price of $1,441.67.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $1550 | $1600 | -3% |
| 2025-12-15 | Wells Fargo | $1450 | $1400 | +4% |
| 2025-12-09 | Goldman Sachs | $1475 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $1550 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 18 ($1.28M) |
| Sells | 6 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (+1.4%)
- Blackrock Inc.: 9.2% (-3.1%)
- State Street Corpora: 4.7% (-0.5%)
- Capital Internationa: 4.2% (+1.2%)
- Bank Of New York Mel: 4.0% (-9.0%)

### Key Risks

1. Valuation stretched: PEG 5.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 5.76 signals overvaluation risk, limited margin of safety. Forward P/E 30.7x stretched relative to 8% growth. Quality metrics strong (ROE 30%, ROA 20%, margin 21%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $28.9B |
| Beta | 1.40 |
| 52W Range | $946.69 - $1525.17 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 5.76 |
| Forward P/E | 30.7 |
| Current P/E | 33.2 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.8% to -2.0% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.0pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-5.29), momentum weakening. RSI neutral at 48. Elevated volume (1.6x 20MA), institutional activity likely. OFD pattern: +SLH (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.01% (CS: 28) | Weak |
| RSI_14 | 48.4 | Neutral |
| MACD Histogram | -5.29 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 1.123x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1402.45
- **Stop Loss:** $1334.09 (4.9% risk)
- **Target:** $1470.81 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 17
- **Position Value:** $23,841.65
- **Portfolio %:** 23.84%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $12.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $10.66 | $11.15 | +4.6% |
| 2025Q2 | $9.60 | $10.09 | +5.1% |
| 2025Q1 | $7.88 | $8.19 | +3.9% |
| 2024Q4 | $11.72 | $12.41 | +5.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*